Clinical-epidemiological profile of patients with thyrotoxic periodic paralysis in two peruvian hospitals
Main Article Content
Keywords
Hyperthyroidism, Hypokalemia, Paralysis, Thyrotoxicosis
Abstract
Background: Thyrotoxic Periodic Paralysis (PPT) is an uncommon complication of hyperthyroidism, it is the most frequent cause of acute flaccid paralysis in adults.
Material and methods: A retrospective observational study was carried out in 2 reference hospitals of the social security in Lima-Peru, which included 22 patients diagnosed with PPT during the period 2014-2021.
Results: the average age at diagnosis was 35.77 ± 9.6 years, all of mixed race, in 82% of the patients the diagnosis of hyperthyroidism was established from this entity, the etiology in 95% was autoimmune (Graves-Basedow) except for one whose etiology was toxic multinodular goiter. The triggering event reported in 54% of patients was the intake of copious food high in carbohydrates, followed by exercise (27%), the most frequent presentation time was during the morning (41% of the cases), the main weakness pattern compromised lower limbs (45% paraplegia, 18% paraparesis), only 36% were diagnosed with PPT in their first episode of motor weakness.
Conclusions: We consider that this condition should be suspected in any young male patient of any ethnicity with acute muscle weakness, associated with low serum potassium levels and symptoms of thyrotoxicosis, although its absence should not rule out the diagnosis. The precipitating factor should be identified as much as possible and initial therapy with propanolol with or without intravenous or oral potassium replacement should be established, with adequate subsequent monitoring to minimize the risk of rebound hyperkalemia.
References
Díaz da Silva MR, Chiamolera MI, Kasamatsu TS, Cerutti JM, Maciel RMB. Paralisia periódica hipocalêmica tirotóxica, uma urgência endócrina: revisão do quadro clínico e genético de 25 pacientes. Arq Bras Endocrinol Metabol. 2004;48(1):196- 215. DOI:10.1590/S0004-27302004000100022.
Calipuy Gálvez JM, Suárez Ale H. Parálisis periódica tirotóxica hipopotasémica. Rev Soc Peru Med Interna. 2010; 23(4):163-6. DOI: 10.36393/spmi.v23i4.388.
Balakrishnan RK, Chandran SR, Thirumalnesan G, Doraisamy N. Thyrotoxic periodic paralysis. Indian J Endocrinol Metab. 2011;15(Suppl 2):147. DOI: 10.4103/2230-8210.83360.
Lin SH. Thyrotoxic Periodic Paralysis. Mayo Clin Proc. 2005; 80(1):99-105. DOI: 10.1016/S0025-6196(11)62965-0.
Maciel RMB, Lindsey SC, Dias Da Silva MR. Novel etiopatho-physiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol. 2011;7:657-67. DOI: 10.1038/nrendo.2011.58.
Meseeha M, Parsamehr B, Kissell K, Attia M. Thyrotoxic periodic paralysis: a case study and review of the literature. J Community Hosp Intern Med Perspect. 2017;7(2):103-6. DOI: 10.1080/20009666.2017.1316906.
Hsieh CH, Kuo SW, Pei D, Hung YJ, Chyi-Fan S, Wu LI, et al. Thyrotoxic periodic paralysis: an overview. Ann Saudi Med. 2004;24(6):418-22. DOI: 10.5144/0256-4947.2004.418.
Neki NS. Hyperthyroid hypokalemic periodic paralysis. Pak J Med Sci. 2016;32(4):1051-2. DOI: 10.12669/pjms.324.11006.
Chang CC, Cheng CJ, Sung CC, Chiueh TS, Lee CH, Chau T, et al. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: Focus on symptomatology and precipitants. Eur J Endocrinol. 2013;169(5):529-36. DOI: 10.1530/EJE-13-0381.
Iqbal QZ, Niazi M, Zia Z, Sattar SBA. A Literature Review on Thyrotoxic Periodic Paralysis. Cureus. 2020;12(8):10-2. DOI: 10.7759/cureus.10108.
Naqi M, Bhatt VR, Pant S, Shrestha R, Tadros M, Murukutla S, et al. A 20-year-old Chinese man with recurrent hypokalemic periodic paralysis and delayed diagnosis. BMJ Case Rep. 2012;bcr0120125541. DOI:10.1136/bcr.01.2012.5541.
Yao Y, Fan L, Zhang X, Xiao Z, Long Y, Tian H. Episodes of paralysis in Chinese men with thyrotoxic periodic paralysis are associated with elevated serum testosterone. Thyroid. 2013;23(4):420-7. DOI: 10.1089/thy.2011.0493.
Sáenz-Bustamante S, Yovera-Aldana M, Churampi-López M, Jáuregui-Macedo N, Delgado-Rojas M, Liviac-Cabrera D, et al. Características clínico-laboratoriales de pacientes con parálisis periódica tirotóxica en el Hospital Nacional Edgardo Rebagliati Martins, 2011-2014. An Fac med. 2014;75(3):280. DOI: 10.15381/anales.v75i3.9789.
Al-Zubeidi H, Demeterco C, Jones KL. Thyrotoxic, hypokalemic periodic paralysis (THPP) in adolescents. J Pediatr Endocrinol Metab. 2015;28(1-2):157-61. DOI: 10.1515/ jpem-2014-0016.
Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Archives of Internal Medicine. 1999;159(6): 601-6. DOI: 10.1001/archinte.159.6.601.
Ozbakir O, Dogukan A, Kelestimur F. The prevalence of thyroid dysfunction among elderly subjects in an endemic goiter area of Central Anatolia. Endocr J. 1995;42(5): 713-6. DOI: 10.1507/endocrj.42.713.
Nakamura S, Sugimoto M, Kosaka J, Watanabe H, Shima H, Kawahira S. Silent thyroiditis with thyroid-stimulationblocking antibodies (TSBAb). Jpn J Med. 1990;29(6):623-7. DOI: 10.2169/internalmedicine1962.29.623.
Cesur M, Bayram F, Temel MA, Ozkaya M, Kocer A, Ertorer ME, et al. Thyrotoxic hypokalaemic periodic paralysis in a Turkish population: three new case reports and analysis of the case series. Clin Endocrinol (Oxf). 2008;68(1):143-52. DOI: 10.1111/j.1365-2265.2007.03014.x.
Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R. Hyperinsulinaemia and Na+, K+ -ATPase activity in thyrotoxic periodic paralysis. Clin Endocrinol (Oxf). 1994;41(2):213-6. DOI: 10.1111/j.1365-2265.1994.tb02532.x.
Levey GS, Klein I. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. Am J Med. 1990;88(6):642-6. DOI: 10.1016/0002-9343(90)90533-j.
Lee KO, Taylor EA, Oh VM, Cheah JS, Aw SE. Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis. Lancet. 1991;337(8749):1063-4. DOI: 10.1016/0140-6736(91)91710-c.
Blanco G, Mercer RW. Isoenzymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol. 1998;275(5):F633-F650. DOI: 10.1152/ ajprenal.1998.275.5.F633.
Wu CC, Chau T, Chang CJ, Lin SH. An unrecognized cause of paralysis in ED: thyrotoxic normokalemic periodic paralysis. Am J Emerg Med. 2003;21(1): 71-3. DOI: 10.1053/ ajem.2003.50005.
Mehta SR, Verma A, Malhotra H, Mehta S. Normokalaemic periodic paralysis as the presenting manifestation of hyperthyroidism. J Assoc Physicians India. 1990;38(49):296-7.
Shifrin A. Endocrine Emergencies. 1st ed. Philadelphia: Elsevier; 2021.
Rone JK, Brietzke SA. Euthyroid thyrotoxic periodic paralysis. Mil Med. 1991;156(8):434-6.
Correia M, Darocki M, Hirashima ET. Changing management guidelines in thyrotoxic hypokalemic periodic paralysis. J Emerg Med. 2018;55(2):252-6. DOI: 10.1016/j. jemermed.2018.04.063.
Falhammar H, Thorén M, Calissendorff J. Thyrotoxic periodic paralysis: clinical and molecular aspects. Endocrine. 2013; 43:274-84. DOI: 10.1007/s12020-012-9777-x.
Tassone H, Moulin A, Henderson SO. The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature. J Emerg Med. 2004;26(2):157-61. DOI: 10.1016/j.jemermed.2003.05.004.
Griggs RC, Resnick J, Engel WK. Intravenous treatment of hypokalemic periodic paralysis. Arch Neurol. 1983;40(9):539- 40. DOI: 10.1001/archneur.1983.04050080039005.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.